NCT05261490 - Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

October 11, 2023

Study Completion Date

February 15, 2024

Conditions

Ovarian CancerOvarian NeoplasmsOvarian CarcinomaFallopian Tube CancerEpithelial Ovarian CancerPrimary Peritoneal Carcinoma

Interventions

DRUG

maplirpacept (PF-07901801)

PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.

DRUG

Pegylated Liposomal Doxorubicin (PLD)

RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2

Trial Locations (18)

15213

Magee-Womens Hospital of UPMC, Pittsburgh

15232

UPMC Hillman Cancer Center-Investigational Drug Services, Pittsburgh

32806

Orlando Health Cancer Institute Gynecologic Cancer Center, Orlando

Orlando Health Cancer Institute, Orlando

33176

Baptist Hospital of Miami, Miami

Miami Cancer Institute at Baptist Health, Inc., Miami

44106

Cleveland Clinic taussig Cancer Center Investigational Pharmacy, Cleveland

44111

Cleveland Clinic Fairview Hospital, Cleveland

44124

Cleveland Clinic Hillcrest Hospital, Mayfield Heights

44195

Cleveland Clinic, Cleveland

48073

Michigan Healthcare Professionals PC, Royal Oak

48126

Michigan Healthcare Professionals PC, Dearborn

48314

Michigan Healthcare Professionals PC, Sterling Heights

48334

Michigan Healthcare Professionals PC, Farmington Hills

57105

Avera Cancer Institute, Sioux Falls

74146

Oklahoma Cancer Specialist and Research Institute. LLC, Tulsa

77024

oncology Consultants, P.A., Houston

90403

Sarcoma Oncology Research Center, Santa Monica